GSA Capital Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

GSA Capital Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.78M	Buy	70,484 +19,286	+38%	+$424K	0.11%	210
2026 Q1	$1.14M	Buy	51,198 +22,998	+82%	+$550K	0.07%	418
2025 Q4	$753K	Sell	28,200 -47,702	-63%	-$1.14M	0.06%	541
2025 Q3	$1.62M	Buy	75,902 +51,428	+210%	+$1.22M	0.14%	149
2025 Q2	$528K	Sell	24,474 -54,819	-69%	-$1.02M	0.04%	878
2025 Q1	$1.32M	Buy	79,293 +5,766	+8%	+$105K	0.12%	219
2024 Q4	$1.35M	Buy	73,527 +6,431	+10%	+$104K	0.1%	234
2024 Q3	$1.03M	Sell	67,096 -113,604	-63%	-$1.9M	0.08%	449
2024 Q2	$2.94M	Buy	180,700 +69,306	+62%	+$1.12M	0.21%	46
2024 Q1	$2.06M	Buy	111,394 +97,987	+731%	+$2.43M	0.16%	93
2023 Q4	$420K	Sell	13,407 -66,442	-83%	-$1.59M	0.04%	909
2023 Q3	$1.66M	Buy	79,849 +57,119	+251%	+$1.55M	0.14%	166
2023 Q2	$544K	Buy	+22,730	New	+$505K	0.05%	693
2022 Q3	–	Sell	-30,447	Closed	-$429K	–	1465
2022 Q2	$429K	Buy	+30,447	New	+$568K	0.06%	592
2021 Q4	–	Sell	-68,330	Closed	-$1.14M	–	1369
2021 Q3	$1.14M	Buy	+68,330	New	+$1.32M	0.12%	250
2020 Q1	–	Sell	-9,486	Closed	-$406K	–	1000
2019 Q4	$406K	Sell	9,486 -1,152	-11%	-$50.1K	0.05%	803
2019 Q3	$383K	Buy	+10,638	New	+$323K	0.05%	721
2018 Q4	–	Sell	-11,717	Closed	-$243K	–	1299
2018 Q3	$243K	Buy	+11,717	New	+$184K	0.01%	1413
2016 Q1	–	Sell	-9,731	Closed	-$347K	–	1627
2015 Q4	$347K	Sell	9,731 -24,977	-72%	-$880K	0.02%	1384
2015 Q3	$1.15M	Sell	34,708 -7,369	-18%	-$307K	0.06%	548
2015 Q2	$1.76M	Sell	42,077 -27,218	-39%	-$1.05M	0.07%	471
2015 Q1	$2.26M	Buy	69,295 +58,062	+517%	+$2M	0.09%	278
2014 Q4	$357K	Buy	+11,233	New	+$319K	0.02%	1160
2014 Q2	–	Sell	-24,751	Closed	-$602K	–	1775
2014 Q1	$602K	Buy	+24,751	New	+$626K	0.04%	655

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GSA Capital Partners's ACAD Position: Q2 2026 in Review

GSA Capital Partners increased its Acadia Pharmaceuticals (ACAD) stake by 38% in Q2 2026, buying an estimated $424K and bringing the position to 70,484 shares worth $1.78M. The position accounts for 0.11% of the portfolio, ranked #210.

GSA Capital Partners first reported a position in ACAD in Q1 2014 and has held it in 24 quarters since. The position peaked at $2.94M in Q2 2024. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

GSA Capital Partners held 70,484 shares of Acadia Pharmaceuticals worth $1.78M as of Q2 2026.
GSA Capital Partners bought 19,286 Acadia Pharmaceuticals shares in Q2 2026, an estimated $424K.
Acadia Pharmaceuticals made up 0.11% of GSA Capital Partners's portfolio in Q2 2026, its #210 holding.
GSA Capital Partners first reported a position in Acadia Pharmaceuticals in Q1 2014 and has held it in 24 quarters since.
GSA Capital Partners's Acadia Pharmaceuticals position peaked at $2.94M in Q2 2024.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.